Imminent liver failure during treatment with ribociclib and letrozole in patient with metastatic breast cancer [1]
IMMINENT LIVER FAILURE DURING TREATMENT WITH RIBOCICLIB AND LETROZOLE IN PATIENT WITH METASTATIC BREAST CANCER
59 years old female presented with primary metastatic breast cancer (bone metastases) in 2018:
- Tumour biology: ER 100%, PR 30%, HER2 negative, Grade II, MIB-1 1 %, PIK3CA mutation found in primary tumour,
- genetic testing negative,
First line treatment with ribociclib and letrozole:
- Drug induced liver injury appeared at the beginning of 4th cycle due to which the drugs were discontinued. After 3 months liver function normalised.
- The patient remained progression free for 3 years with anastrozole monotherapy till 1/2022 and with no consequences regarding liver toxicity.
From then on the disease is progressing more quickly – she is now receiving 4th line of therapy with capecitabine.